A company in northern California developing a test for the early detection of colorectal cancer has received six patents for its product. Sunnyvale, California-based CellMax Life said Tuesday it was ...

CellMax Life, the precision cancer testing company, announced the immediate availability in the United States of the CellMax-DNA Genetic Cancer Risk Test, which examines 98 genes across 24 hereditary ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--CellMax Life, the precision cancer testing company, announced today the commercial availability of CellMax-LBx Liquid Biopsy in India. CellMax-LBx is a cancer blood ...

SUNNYVALE, Calif. and ROSWELL, Ga., March 23, 2021 /PRNewswire/ -- CellMax Life, a molecular diagnostics company with proprietary technology for pre-cancer and cancer detection blood tests, and Sebela ...

Data shows 92% sensitivity for colorectal cancer and 55% sensitivity for precancerous advanced adenomas at 91% specificity. Data to be presented at ASCO Gastrointestinal Cancers Symposium The data ...

SUNNYVALE, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- CellMax Life, a molecular diagnostics company, announced today that its FirstSight™ pre-cancer and cancer detection blood test has received ...

Today, the majority of cancer cases are detected late stage, which unfortunately means most patients don't survive the disease. Despite advances in medical technology and clinical care, most cancer ...

In “Round B” of funding for the biometrics startup, CellMax, the company was able to raise $2 million to further advance its proprietary VioMetric technology. This, after collecting $1.3 million in ...

CellMax Life Inc. is joining a race to ease the process of detecting colon cancer in its earliest and most treatable stages, raising $9 million in Series A-1 financing and introducing a blood-based ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--CellMax Life, the precision cancer testing company, announced today the immediate availability in India of the CellMax-DNA Genetic Cancer Risk Test, which examines ...

Patents cover entirety of sub-$200 test and platform, which isolates rare circulating tumor cells (CTCs) from one tube of blood CellMax Life, enabling early cancer detection and management with ...